In-depth trading ideas

Discover detailed market analysis from traders. See how others approach this instrument, compare different strategies, and discover perspectives that can shape your own view.

RDHL has a fresh catalyst and lots of eyes on it Although not my favorite type of play, this mid-float stock has a VERY VOLATILE chart and has made BIG RUNS in the past... followed by BIG DROPS! IF momentum comes in, we are about to break an important level that could push this stock passed .80's... then ANYTHING can happen. INTRADAY play for me. GL HF

by CandyMan_Trader

RDHL Stock (Redhill Biopharma Ltd. - American Depositary Shares RedHill Biopharma files to sell 8.86M American Depositary Shares for holders

RDHL | Good Entry Point | LONG RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study

by DivergenceSeeker

Break out for Redhill Biopharma (RDHL)See chart

by coldsteel_trading

NASDAQ: RDHL / RedHill Biopharma Ltd Hi. Look at this beauty. If you want new shares, like wildly and follow wildly. It is my personal opinion. It isn't investment advice.

by UnknownUnicorn7851950

RDHL, enters Downtrend as Momentum drops below 0 level 09/29/20 This indicator may be signaling that RDHL's price has further to drop, since it fell below its price logged 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options. Tickeron A.I.dvisor backtested 85 similar cases where RDHL's Momentum Indicator fell below the 0 level, and 71 of them led to a successful outcome. Odds of Success: 84%. Current price $10.32 is above $8.25 the highest resistance line found by Tickeron A.I. Throughout the month of 08/27/20 - 0

RedHill Biopharma Announces Positive Recommendation from Indepen RDHL: RedHill Biopharma Ltd. 2020-08-27 07:00:10 RedHill Biopharma Announces Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy

by RocketTickers

RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 St RDHL: RedHill Biopharma Ltd. 2020-07-31 07:00:10 RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 Study with RHB-204 for NTM Infections

by RocketTickers

RDHL Long Personally I think the stock is forming a pullback before another surge, I do believe this stock has the potential to reach $20 in the future.

$RDHL - The "Savior" 6.5$Resistance 7.7, and above is 8. Not for a suggestion Just an Idea.

by Samuel12_1980

RedHill Biopharma Receives FDA Approval for COVID-19 Clinical St RDHL: RedHill Biopharma Ltd. 2020-05-08 07:00:10 RedHill Biopharma Receives FDA Approval for COVID-19 Clinical Study with Opaganib in the U.S.

by RocketTickers

$RDHL - Next level within closing above 7 only The first two patients have been treated with opaganib at a leading hospital in Israel. At the time of treatment initiation, both patients suffered from moderate to severe acute respiratory symptoms related to SARS-CoV-2 infection, required supplemental oxygenation and were hypoxic despite being treated with maximum flow of oxygen with cannulas. Preliminary findings from both patients demonstrated clinical improvement within days post treatment-initiation with opaganib. To date, both patients h

by Samuel12_1980

$RDHL - Few prices above 6.3 2 main resistance are 6.48 and 7 Target to 8.38 - 8.54 (Talicia's FDA Announcement). Below is 5.8 and MA200 Not for a suggestion!

by Samuel12_1980

$RDHL - As I wrote so, few days ago Looks great!

by Samuel12_1980

RedHill Biopharma Ltd. on breakout watch RedHill Biopharma Ltd. is a biopharmaceutical company focusing on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases. It operates through the Commercial Operations segment and the Research & Development segment. The Commercial Operations segment covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Company's subsidiary in the United States. The Research & Deve

$RDHL - Technically looks great 2 main supports located on Moving average 50, 20 SHS option with target to 7.13~ Not for suggestion Good-luck to all

by Samuel12_1980

$RDHL - " Talicia® available through pharmacies nationwide."TEL-AVIV, Israel and RALEIGH, N.C., March 13, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company focused on gastrointestinal diseases, today announced that Express Scripts has added Talicia® (omeprazole magnesium, amoxicillin and rifabutin)1 to its National Preferred Formulary as a preferred brand. RedHill recently launched Talicia® in the U.S., making Talicia® available through pharmacies nationwide. “The addition

by Samuel12_1980

$RDHL - area 5.2 was good for support I hope we will see upturn to the a higher price values. Not for suggestion. Just an Idea In today.

by Samuel12_1980

$RDHL - Is that bearish or bullish triangle? TALICIA Q1 2020 Into the market this quarter Good-luck to the company and do not see it as suggestion!

by Samuel12_1980

$RDHL - Aemcolo® and Talicia® in Q4/2019 and Q1/2020 • U.S. FDA approval of Talicia® for the treatment of Helicobacter pylori infection in adults • Strategic partnership with Cosmo Pharmaceuticals, including investment of $36.3 million and exclusive rights to commercialize Aemcolo® in the U.S. for travelers’ diarrhea • Accelerating expansion of commercial sales team in the U.S. ahead of planned launches of Aemcolo® and Talicia® in Q4/2019 and Q1/2020, respectively • Debt-free balance sheet with approximately $59 million as of October 22, 20

by Samuel12_1980

$RDHL - FDA Approved today RHB-105 RedHill plans to launch Talicia®1 in the U.S. in Q1/2020 for the treatment of H. pylori infection in adults, targeting more than two million patients estimated to be treated for H. pylori infection annually Talicia® is the first and only FDA approved rifabutin-based H. pylori therapy and is designed to address the high and growing bacterial resistance and diminished efficacy of clarithromycin-based standard-of-care therapy H. pylori affects approximately 35% of U.S. adult population; it is

by Samuel12_1980

$RDHL In today for Talicia results (RHB-105) Technically above 6.5 - good All of the above at your discretion, your accepted trading rules, trading strategies and your preferred trading management. This is not a recommendation to buy or sell.

by Samuel12_1980

$RDHL Very critical month (November 2): Key Highlights and Upcoming Milestones: U.S. FDA acceptance of the New Drug Application (NDA) for Talicia® for H. pylori for priority review and assignment of a target PDUFA action date of November 2, 2019 • Preparations ongoing for the potential U.S. commercial launch of Talicia® in Q4/2019, subject to FDA approval, with RedHill’s established sales force, led by the Company’s experienced commercial management team • FDA meetings planned to take place in H2/

by Samuel12_1980